Clinical Application of FL-091 Radionuclide Imaging in Diagnosis and Staging of Malignant Tumors

Active, not recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

October 25, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Malignant Tumors With Positive NTSR1 Expression
Interventions
DIAGNOSTIC_TEST

Specific positron imaging agents targeting NTRS-1(FL-091)

This study is diagnostic. Oncologists screen patients with malignant tumors such as head and neck cancer, colorectal cancer, and pancreatic adenocarcinoma who are clinically suspected or confirmed; investigators talk to patients who meet the inclusion criteria, explain the study purpose and study process, sign informed consent forms, and patients can complete 68Ga-FL-091PET imaging and 111In-FL-091SPECT imaging respectively in outpatient or inpatient periods. General information, clinical data, blood routine, urine routine, liver and kidney function and other biochemical indicators, electrocardiogram, radionuclide imaging results and other imaging data of the patients participating in the study were collected and compared with histopathology to evaluate the value of both imaging in the diagnosis of head and neck cancer, colorectal cancer, and pancreatic adenocarcinoma.

Trial Locations (1)

430030

Wuhan Union Hospital,China, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT06977945 - Clinical Application of FL-091 Radionuclide Imaging in Diagnosis and Staging of Malignant Tumors | Biotech Hunter | Biotech Hunter